Screening compounds for potential safety problems during late lead optimization
As a project moves forward through lead optimization, sufficient quantities of compound are synthesized to enable short-term in vivo treatments. The broad selection of in vivo toxicological Drug Signatures and biological pathways in ToxFX can predict safety problems or unanticipated off-target effects in liver, heart or kidney.

Prioritizing compounds
Compounds that show similar efficacy may differ dramatically in their toxicological profiles. ToxFX makes it possible to use an early toxicogenomic assessment of relative safety as an additional criterion for choosing between compounds to advance without slowing the progress of the development program.

Confirming safety
For a small additional effort and expense, ToxFX makes it possible to survey compounds for a broad collection of potential safety problems. The absence of any apparent problem in a ToxFX analysis offers additional evidence of safety that can be used to support a decision to advance a compound.

Predicting potential safety problems
ToxFX can be applied after short-term in vivo treatments. Gene expression is highly sensitive and results from an analysis often predict safety issues before they can be seen with conventional methods such as clinical chemistry and pathology.